<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">42971</article-id><article-id pub-id-type="doi">10.18821/1028-9984-2018-23-3-6-134-142</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">APPLICATION OF PHOTODYNAMIC THERAPY IN COMPLEX TREATMENT OF PATIENTS WITH MALIGNANT NEOPLASMS OF PANCREAS AND BILIAR TRACT. REVIEW</article-title><trans-title-group xml:lang="ru"><trans-title>ПРИМЕНЕНИЕ ФОТОДИНАМИЧЕСКОЙ ТЕРАПИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ БОЛЬНЫХ ЗЛОКАЧЕСТВЕННЫМИ НОВООБРАЗОВАНИЯМИ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ И ЖЕЛЧЕВЫВОДЯЩЕЙ СИСТЕМЫ. ОБЗОР</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tseimakh</surname><given-names>A. E</given-names></name><name xml:lang="ru"><surname>Цеймах</surname><given-names>А. Е</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lazarev</surname><given-names>A. F</given-names></name><name xml:lang="ru"><surname>Лазарев</surname><given-names>А. Ф</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kurtukov</surname><given-names>V. A</given-names></name><name xml:lang="ru"><surname>Куртуков</surname><given-names>В. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tseimakh</surname><given-names>M. E</given-names></name><name xml:lang="ru"><surname>Цеймах</surname><given-names>М. Е</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shoykhet</surname><given-names>Ia. N</given-names></name><name xml:lang="ru"><surname>Шойхет</surname><given-names>Я. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Altai State Medical University of Ministry of Health Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Алтайский государственный медицинский университет» Министерства здравоохранения РФ</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Altai branch of Russian Cancer Research Center named after N.N. Blokhin of Ministry of Health Russia</institution></aff><aff><institution xml:lang="ru">Алтайский филиал ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Министерства здравоохранения РФ</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">State hospital №5</institution></aff><aff><institution xml:lang="ru">КГБУЗ «Городская больница № 5</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2018</year></pub-date><volume>23</volume><issue>3-6</issue><issue-title xml:lang="en">VOL 23, NO3-6 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 23, №3-6 (2018)</issue-title><fpage>134</fpage><lpage>142</lpage><history><date date-type="received" iso-8601-date="2020-08-24"><day>24</day><month>08</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Эко-Вектор"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/42971">https://rjonco.com/1028-9984/article/view/42971</self-uri><abstract xml:lang="en"><p>Data from the global oncology statistics shows that pancreatic cancer is at the 4th place in the world for mortality in men and women, having the lowest five-year life expectancy among gastrointestinal tumors with an average median survival of no more than 6 months. Along with it, malignant neoplasms of the biliary tract are rare in the frequency of occurrence of the nosological group of diseases, which, however, are on the second place in terms of the level of malignancy among the neoplasms of the liver. Both nosologies in the vast majority are not subject to radical treatment, being the object of palliative treatment due to late diagnosis. Despite the establishment of new medical technologies, the main method of treating of these nosologies remains surgical. However, at the time of detection and diagnosis less than 20% of patients have a resectable process, and, moreover, even patients with a resectable tumor are often not subjected to radical surgical treatment due to dissemination of the tumor at the time of surgery, which reduces the postoperative five-year survival of this cancer: 25-30% in patients without metastases to regional lymph nodes and about 10% in patients with metastases to regional lymph nodes. Due to the low efficiency of the surgical method, there are searched new methods of complex treatment, new drugs and chemotherapy regimens, as well as radiotherapy regimens, however, with the improvement of methods for diagnosing cancer in the past 20-25 years, neither the prognosis nor survival of patients nor the percentage of early diagnosis of cancer of the pancreas did not significantly improve. A new and promising method for the treatment of malignant neoplasms of the pancreas and the biliary tract is photodynamic therapy, the undoubted advantage of which is low toxicity, selective effect only on cancer cells at the fundamental level, contributing depending on the duration of exposure to their autophagy, apoptosis or necrosis. And, although PDT has drawbacks connected with side effects of PDT, such as gastrointestinal bleeding, obstruction of the duodenum and hemorrhagic pancreonecrosis, and with insufficient knowledge and lack of clear recommendations, but the PDT method is certainly a promising method in both radical and in palliative complex therapy of malignant neoplasms of the pancreas and biliary tract, which requires further study.</p></abstract><trans-abstract xml:lang="ru"><p>Данные мировой онкологической статистики показывают, что рак поджелудочной железы находится на 4-м месте в мире по смертности у мужчин и женщин, имея самую низкую 5-летнюю продолжительность жизни среди гастроинтестинальных опухолей со средней медианой выживаемости не более 6 мес. Наряду с ним злокачественные новообразования желчевыводящей системы являются редкой по частоте встречаемости нозологической группой заболеваний, которые, однако, находятся на 2-м месте по уровню злокачественности среди новообразований печени. Обе нозологии в абсолютном большинстве не подвержены радикальному лечению, являясь объектом паллиативного лечения вследствие поздней диагностики. Несмотря на внедрение новых медицинских технологий, основным методом лечения данной нозологии остаётся хирургический. Однако на момент выявления и постановки диагноза менее 20% пациентов имеют резектабельный процесс, и, более того, даже пациенты с резектабельной опухолью часто не подвергаются радикальному хирургическому лечению из-за диссеминации опухоли к моменту операции, что снижает послеоперационную 5-летнюю выживаемость этого рака: до 25-30% пациентов без метастазов в регионарные лимфоузлы и около 10% пациентов с метастазами в регионарные лимфоузлы. Вследствие малой эффективности хирургического метода продолжается поиск новых методов комплексного лечения, новых препаратов и схем химиотерапии, а также режимов лучевой терапии, однако при улучшении методов диагностики онкологических заболеваний за последние 20-25 лет ни прогноз, ни выживаемость пациентов, ни процент ранней диагностики рака поджелудочной железы значимо не улучшились. Новым и перспективным методом лечения злокачественных новообразований поджелудочной железы и желчевыводящей системы является фотодинамическая терапия (ФДТ), несомненным преимуществом которой является низкая токсичность, избирательное воздействие лишь на раковые клетки на фундаментальном уровне, способствуя в зависимости от длительности воздействия их аутофагии, апоптозу или некрозу. И хотя у ФДТ имеются и недостатки, связанные как с побочными эффектами ФДТ, такими как гастроинтестинальные кровотечения, обструкция ДПК и геморрагические панкреонекрозы, так и с недостаточной изученностью и отсутствием чётких рекомендаций, ФДТ, безусловно, является перспективным методом в радикальной и паллиативной комплексной терапии злокачественных новообразований поджелудочной железы и желчевыводящей системы, требующим дальнейшего изучения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>malignant neoplasm of pancreas</kwd><kwd>malignant neoplasm of biliary tract</kwd><kwd>photodynamic therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>злокачественное новообразование поджелудочной железы</kwd><kwd>злокачественное новообразование желчевыводящей системы</kwd><kwd>фотодинамическая терапия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin. Oncol. 2015; 42: 8-18.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Клинические рекомендации. Рак поджелудочной железы. [Еlectronic resource]. Ассоциация онкологов России - 2017. 36 с. Access mode: http://oncology-association.ru/files/clinical-guidelines_adults/rak_podzheludochnoy_zhelezy.pdf</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Wei Li, Qingyong Ma, and Erxi Wu Perspectives on the Role of Photodynamic Therapy in the Treatment of Pancreatic Cancer. International Journal of Photoenergy. 2012; Article ID 637429: 9.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2018. 236 с.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Evan L. Fogel, Safi Shahda, Kumar Sandrasegaran et al. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am. J. Gastroenterol. 2017; 112 (4): 537-54.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Alette Ruarus, Laurien Vroomen, Robbert Puijk et al. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers. 2018; 10, 16: 1-18.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Benjamin Meier and Karel Caca. Endoscopic and Photodynamic Therapy of Cholangiocarcinoma. Visc. Med. 2016; 32 (6): 411-3.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Клинические рекомендации Билиарный рак. [Еlectronic resource] Ассоциация онкологов России - 2017. 37 с. Access mode: http://oncology-association.ru/files/clinical-guidelines_adults/rak_zhelchevyvodyashey_sistemy.pdf</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gillen S., Schuster T., zum Büschenfelde C.M. et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Evans D.B., Varadhachary G.R., Crane C.H. et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J. Clin. Oncol. 2008; 26: 3496-502</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Loehrer P.J., Sr, Feng Y., Cardenes H.R. et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 2011; 29: 4105-12. [PMC free article]</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hammel P., Huguet F., Van Laethem J.-L. et al. Comparison of chemo-radiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J. Clin. Oncol. 2013; 31(Suppl) abstr LBA4003.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chauffert B., Mornex F., Bonnetain F. et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 2008; 19: 1592-9</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Burris H.A., 3rd, Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin. Oncol. 1997; 15: 2403-13</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Conroy T., Desseigne F., Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011; 364: 1817-25</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>120. Faris J.E., Blaszkowsky L.S., McDermott S. et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. 2013; 18: 543-8. [PMC free article]</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Katz M.H.G., Shi Q., Ahmad S.A. et al. Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101. J. Clin. Oncol. 2015; 33 (Suppl) abstr 4008.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F., et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 2013; 31: 23-9</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Oettle H., Riess H., Stieler J., et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol. 2014; 32: 2423-9</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Von Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013; 369: 1691-703. [PMC free article]</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Herman J.M., Chang D.T., Goodman K.A., et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 1128-37. [PMC free article]</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Regine W.F., Winter K.A., Abrams R. et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann. Surg. Oncol. 2011; 18: 1319-26. [PMC free article]</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hsu C.C., Herman J.M., Corsini M.M. et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann. Surg. Oncol. 2010; 17: 981-90. [PMC free article]</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Huguet F., Hammel P., Vernerey D. et al. Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study. J. Clin. Oncol. 2014; 32(Suppl):4001.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Schellenberg D., Goodman K.A., Lee F. et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiation therapy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 678-86</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Valle J., Wasan H., Palmer D.H. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010; 362: 1273-81. doi: 10.1056/NEJMoa0908721.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lee J., Park S.H,. Chang H.M. et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012; 13: 181-8. doi: 10.1016/S1470-2045(11)70301-1</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clinics in Dermatology. 2006; 24 (1): 16-25.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Zhao B., He Y. Y. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Review of Anticancer Therapy. 2010; 10 (11): 1797-809.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Jerjes W., Upile T., Akram S., Hopper C. The surgical palliation of advanced head and neck cancer using photodynamic therapy. Clinical Oncology. 2010; 22 (9): 785-91.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Wildeman M.A., Nyst H.J., Karakullukcu B., Tan B.I. Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer. Head &amp; Neck Oncology. 2009; 1: article 40.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Chen M., Pennathur A., Luketich J.D. Role of photodynamic therapy in unresectable esophageal and lung cancer. Lasers in Surgery and Medicine. 2006; 38 (5): 396-402.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Ducreux M., Cuhna A. Sa., Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: 56-68.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Yusuf T. E., Matthes K., Brugge W.R. EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointestinal Endoscopy. 2008; 67 (6): 957-61.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Leggett C.L., Gorospe E.C., Murad M.H. Montori V.M., Baron T.H., Wang K.K. Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn. Ther. 2012; 9:189-95.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Lu Y., Liu L., Wu J.C., Bie L.K., Gong B. Efficacy and safety of photodynamic therapy for unresectable cholangiocarcinoma: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 2015; 39:718-24.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Yang J., Shen H., Jin H., Lou Q., Zhang X. Treatment of unresectable extrahepatic cholangiocarcinoma using hematoporphyrin photodynamic therapy: a prospective study. Photodiagnosis Photodyn. Ther. 2016 DOI: 10.1016/j.pdpdt.2016.10.001</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Jain S., Kockelbergh R.C. The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer. BJU International. 2005; 96 (1): 17-21.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Robertson C.A., Evans D.H., and Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. Journal of Photochemistry and Photobiology B. 2009; 96 (1):1-8.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Bown S.G., Rogowska A.Z., Whitelaw D.E. et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002; 50 (4): 549-57.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Tseng W.W., Saxton R.E., Deganutti A. and Liu C.D. Infrared laser activation of indocyanine green inhibits growth in human pancreatic cancer. Pancreas. 2003; 27 (3): e42- e45.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Huggett M.T., Jermyn M., Gillams A. et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br. J. Cancer. 2014; 110, 1698-704.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Park D.H, Lee S.S, Park S.E. et al. Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur. J. Cancer. 2014; 50: 1259-68.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Wentrup R., Winkelmann N., Mitroshkin A. et al. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma. Gut Liver. 2016; 10: 470-75.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Xie Q., Jia L., Liu Y.H., Wei C.G. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World Journal of Gastroenterology. 2009; 15 (6): 737-41.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>National Comprehensive Cancer Network. NCCN Guidelines Version 2.2015. Pancreatic Adenocarcinoma. http://www.nccn.org.</mixed-citation></ref></ref-list></back></article>
